Since Lynch syndrome does not display a specific phenotypic expression allowing its diagnosis, combinations of clinical guidelines (Amsterdam criteria, Bethdesda guidelines) and the molecular tumor characteristics (MSI, IHC, BRAF mutation status) are applied to select patients for genetic analysis of mutations in MMR genes [21–24]. Here, BRAF is linked to neoplasm.